Monitoring Agency Report for quarter ended September 30, 2026: nil deviation in use of IPO proceeds
Gaudium IVF and Women Health Ltd has shared the Monitoring Agency Report from Infomerics Valuation and Rating Limited for the quarter ended September 30, 2026.
By ScoutQuest · · 2 min read
- IPO Size
- Rs.90.00 crore
- Deviation from objects of issue
- Nil
- Range of deviation
- Nil
What the update says
The company has submitted the Monitoring Agency Report for the quarter ended September 30, 2026, prepared by Infomerics Valuation and Rating Limited, the monitoring agency appointed for its Initial Public Offer (IPO).
Amount covered
The report relates to the IPO aggregating to Rs.90.00 crore.
Deviation from the objects
- Deviation from the objects of the issue: Nil
- Range of deviation: Nil
The "objects of the issue" are the purposes for which the company said it would use the money raised in the IPO. A nil deviation means the agency, in its review, found the spending in line with those stated purposes for the quarter.
How the agency reviewed
The monitoring agency states that it examined bank statements of the monitoring account, utilisation certificates issued by the statutory auditor, relevant board resolutions, supporting invoices relating to issue expenses and other management representations it considered necessary for verification of utilisation of proceeds.
What the agency confirms
The agency declares that the report provides an objective view of the utilisation of the issue proceeds in relation to the objects of the issue, and that it gives a true and fair view of the utilisation of the issue proceeds. It also states it has no direct or indirect interest in, or relationship with, the issuer, promoters, directors or management.
What this means for a retail investor
- This is a periodic disclosure that lets shareholders track whether IPO money is being spent as promised.
- A nil deviation is the neutral, clean outcome in such a report; it indicates no diversion from stated objects for the quarter.
- The agency also notes that it does not perform an audit and does not independently verify the information and certificates it receives, which is part of the standard wording of such reports.
Also from Gaudium IVF and Women Health
Gaudium IVF uploads audio recording of Q2/H1 FY27 earnings call held November 16, 2026
16 Nov 2026
Gaudium IVF Q2 FY27: revenue up 17.90% to Rs. 3,741.11 lakhs, EBITDA down 2.13% as new hubs ramp up
15 Nov 2026
Paid-up equity share capital figure corrected to Rs. 3,639.34 lakhs in consolidated results
13 Nov 2026
More numbers
- IPO amount covered by the monitoring agency reportRs.90.00 crore
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.